

# INTERNATIONAL JOURNAL OF PHARMACOLOGY AND CLINICAL SCIENCES

## INFORMATION FOR AUTHORS

[www.ijpcs.net](http://www.ijpcs.net)

---

International Journal of Pharmacology and Clinical Sciences (IJPCS) accepts articles in the form of original research articles (full length original articles or short communications), reviews, letter to editor, editorial, case report and new drug information.

The work submitted should not have been published before as a part or whole (except as abstract) and not under consideration for publication elsewhere. Authors are also required to state during submission that no part of the manuscript has been copied from any source and permission to reproduce table(s) and/or figure(s), (if any) has been obtained. Authors are also expected to mention previous publication/ presentations, if any. All authors should have contributed substantially to the study and to the preparation of the manuscript.

Journal requirements for the manuscripts are in accordance with the Uniform Requirement for Manuscripts Submitted to Biomedical Journals, 2010. For further details refer [www.icmje.org](http://www.icmje.org)

All research must have been conducted after taking permission from appropriate ethics committee and/or regulatory bodies and conducted according to regional and/or national guidelines. All submitted articles will be checked for plagiarism and redundant submission at different stages of article processing.

Articles should be submitted to the editor through online submission system:

<http://emanuscript.in/submissions/index.php/ijpcs/user/register>


The article can also be submitted as an attachment to the following E-mail:

[chiefeditor.ijpcs@gmail.com](mailto:chiefeditor.ijpcs@gmail.com)

## EDITORIAL PROCESS:

The Manuscript review process followed by IJPCS is given in the **Fig 1**. On submission, editors review all submitted manuscripts initially for suitability for formal review. The submitted manuscripts that are not as per the “Instructions to Authors” would be returned to the authors for correction. The journal will not consider any paper which is ethically unacceptable.

**Figure 1: Manuscript review process of International Journal of Pharmacology and clinical Sciences (IJPCS)**



Manuscripts that are found suitable for publication in IJPCS are sent to expert reviewers after blinding. The journal follows a double-blind review process, wherein the reviewers and authors are unaware of each other's identity. The comments and suggestions received from reviewers are conveyed to the corresponding author and the authors are requested to submit a revised version of the manuscript.

The Editorial Board reserves the right to edit all articles for purposes of style, format and clarity. Page proofs of accepted manuscripts are sent to the corresponding author. The corresponding author has to return the corrected proofs to the editor through e-mail.

## **MANUSCRIPT PREPARATION:**

---

Articles should be written in American English.

### **Text formatting:**

Manuscripts should be submitted in MS Word format. The article should be typed with double spacing, with 12-point font and 2.5 cm margins. Abbreviations should be defined at first mention and used consistently thereafter. If authors wish to mention drug names, generic names of drugs and chemicals are preferred; if trade names are used, the generic name should be given at least at first mention. Manuscript should contain the following: Covering letter, Title page, Abstract and Keywords, Text, Acknowledgment (if any), Conflict of interest (if any), References, Tables and Figures.

### **1. Covering letter:**

This needs to be prepared as per the [format given by the journal](#). This is required only for email submission.

**2. Title Page:** This is required only for email submission. The title page includes;

- (a) The type of manuscript (original article, review article, Letter to editor, etc.)
- (b) Concise and informative title of the manuscript
- (d) Full names of all authors (with their highest academic degrees, designation and affiliations)
- (e) Corresponding author name with postal address, email address, telephone and fax numbers

### **3. Abstract and key words:**

Abstract must start on a new page. All original full length articles should contain a structured abstract with not more than 250 words under the following headings: Background, objectives, Methods and Material, Statistical analysis used, Results and Conclusions. Articles on clinical trials should contain abstracts that include the items that the CONSORT group has identified as essential (<http://www.consort-statement.org/?%20=1190>). Review articles, short communications, information of a new drug and case report should be sent with unstructured abstract of not more than 200 words. Abstract is not required for other types of articles.

All abstracts should be followed by 4-5 key words.

### **4. Text:**

#### **A. Original articles:**

Authors are encouraged to use the format while preparing the article.

The text of amounting to up to 3000 words for full length original articles and 1500 for short communications should be divided into following sections, Introduction, Material and

Methods, Results, and Discussion. Each of these sections should begin on a separate page. Authors may use subheadings within some sections to clarify their content

### **Introduction**

Introduction should be brief summarizing the current knowledge of the research area, lacunae in the knowledge and justification for the study aim and objectives.

### **Materials and methods**

This section should provide enough information for readers to critically appraise or repeat the study exactly in the same way as it was done by the authors. This section should mention the study period (duration), study design, how the sample size was calculated, details of inclusion and exclusion criteria, how the randomization was done and other technical points like methods, apparatus and procedures. Studies involving ethical issues must contain a statement that their studies have been reviewed by the appropriate ethics committee. When reporting experiments on human subjects, authors should indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study. When reporting experiments on animals, authors should indicate whether the institutional and national guide for the care and use of laboratory animals was followed. The details of statistical tests used and the level of significance should be stated at the end of this section.

## **Results**

Results should start with baseline parameters and comparison of groups. Present your results in logical sequence in the text, tables, and illustrations, giving the main or most important findings first. Do not repeat the data given in the table or figure or illustrations in the text; emphasize or summarize only important observations with appropriate reference to tables and/or figures and /or illustrations.

## **Discussion**

Discussion should include summary of the key findings, provide the authors' interpretation of the meaning of the study findings in the context of already available literature, highlight strengths and limitations of the study and suggest areas of future research. Conclusion should include a precise summary of the important findings linked with the goal of the study and a clear take home message.

## **B. Review articles:**

The word count for review articles is up to 4000. The section titles would depend upon the topic reviewed. Authors submitting review article should include a section describing the methods used for locating, selecting, extracting, and synthesizing data.

## **C. Letter to editor:**

These should be short research observations or remarks or queries on recently published articles in IJPCS. The letter could have up to 500 words and 5 references.

#### **D. New drug information:**

This section is intended to give a comprehensive review of new drugs that have become recently available for use in human beings. The section titles would depend upon the topic reviewed. Authors submitting review article should include a section describing the methods used for locating, selecting, extracting, and synthesizing data.

#### **E. Case reports:**

Interesting cases and unusual adverse drug reactions can be reported. These communications should have the following headings: Abstract (unstructured), Key-words, Introduction, Case report, Discussion.

#### **F. Editorials:**

These are invited comments on recent advances or original research that will be published in the same issue of the journal.

### **5. References:**

This section must start in a new page.

Reference citing and styling: references should be cited with Arabic numbers in squared parentheses in the text. These references should be listed in the reference section of the manuscript in the numerical order in which they appear in the text. The list of references should be typed double spaced in the Vancouver style. For further details refer [www.icmje.org](http://www.icmje.org).

The list of references should only include papers that have been published or accepted for publication. Personal communications and unpublished works should only be mentioned in the text.

The commonly cited types of references are shown here, for other types of references please refer to ICMJE Guidelines (<http://www.icmje.org> or [http://www.nlm.nih.gov/bsd/uniform\\_requirements.html](http://www.nlm.nih.gov/bsd/uniform_requirements.html)).

### **Articles in Journals**

a. Standard journal article (for up to six authors):

1. Devi V, Shankar PK. Ramelteon: A melatonin receptor agonist for the treatment of insomnia. *J Postgrad Med* 2008;54(1):45-8.

b. Standard journal article (for more than six authors, list first six authors followed by et al)

1. Shrestha J, Shanbhag T, Shenoy S, Amuthan A, Prabhu K, Sharma S, et al. Antiovolatory and abortifacient effects of Areca catechu (betel nut) in female rats. *Indian J Pharmacol* 2010;42(5):306-11.

### **Books:**

a. Personal author(s)

1. Murray PR, Rosenthal KS, Kobayashi GS, Pfaller MA. *Medical microbiology*. 4th ed. St. Louis: Mosby; 2002.

b. Editor(s), compiler(s) as author

1. Gilstrap LC 3rd, Cunningham FG, VanDorsten JP, editors. *Operative obstetrics*. 2nd ed. New York: McGraw-Hill; 2002.

c. Chapter in a book

1. Meltzer PS, Kallioniemi A, Trent JM. Chromosome alterations in human solid tumors. In: Vogelstein B, Kinzler KW, editors. The genetic basis of human cancer. New York: McGraw-Hill; 2002. p. 93-113.

## 6. Tables:

Each table must be typed with double-spacing on a fresh page of the manuscript. All tables are to be serially numbered using Arabic numerals. Number tables consecutively in the order of their first citation in the text and supply a brief title for each. Give each column a short or an abbreviated heading. Authors should place explanatory matter in footnotes, not in the heading. Explain all nonstandard abbreviations in footnotes, and use the following symbols, in sequence: \*, †, ‡, §, ||, ¶, \*\*, ††, ‡‡, §§, ||||, ¶¶, etc. The tables along with their number should be cited at the relevant place in the text. Be sure that each table is cited in the text. The desired positions of tables in the text should be indicated.

**7. Figures:** Figures must be submitted, in the form of TIFF or JPG (JPEG) files separately.

All figures are to be numbered using Arabic numerals according to the order in which they have been first cited in the text. Desired positions of figures in the text should be indicated along with their legends at the end of the manuscript after tables.

**8. Short title** (with less than 50 characters) to be used as running head

**9. Source(s) of support** in the form of grants, equipment, drugs, or all of these.

**10. Acknowledgements:** Contributions that need acknowledging but do not justify authorship, and should specify the nature of support.

**11. Conflicts of Interest:** conflicts of interest, if any, must be declared in this section. If no conflict exists, authors should state: The authors declare that they have no conflict of interest. This section must be included below the acknowledgement section.

**12. Copyright:** Any article accepted for publication/published in the IJPCS will be the copyright of the journal. Authors would be required to mention transferring copyright to the journal in the copyright form while submitting the manuscript. This needs to be prepared as [per the format given by the journal](#).

### **PUBLICATION CHARGES**

For original article, Review article - Rs. 4000 (Foreign author - USD 200)

Short communications, case report, information on new drug - Rs.2000 (USD - 100)

*Note:* Request for waiving / discount in publication charge will be considered on a case-by-case basis and will be granted if the author genuinely does not have the ability to pay. Authors should submit a waiver or discount request during the submission of their article.

### **REQUEST FOR REPRINTS**

The authors can purchase the reprints for which the request may be made after the acceptance of the manuscript. The charges will be informed to the authors based on the page numbers.